Eisai Joins Up With Valeant To Promote Halaven

After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant’s PharmaSwiss division will distribute Halaven (eribulin) in Bulgaria, Romania, Latvia,

Continue Reading

Pharmaceutical Industry Should Invest Further in Anti-Obesity Drugs

Pharmaceutical organisations should increase their investment in anti-obesity drugs to respond to the rising number of clinically obese people globally. This is the main message from a report by business intelligence specialist, GlobalData, which observes that the obesity market is lucrative, largely driven by the embracement of sedentary lifestyles, high cholesterol diets and reduced physical

Continue Reading